• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Clinical outcomes of coronavirus disease 2019 (COVID-19) in cancer patients with prior exposure to immune checkpoint inhibitors.

作者信息

Wu Qiuji, Chu Qian, Zhang Hongyan, Yang Bin, He Xudong, Zhong Yahua, Yuan Xianglin, Chua Melvin L K, Xie Conghua

机构信息

Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, 430071, P. R. China.

Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, 430071, P. R. China.

出版信息

Cancer Commun (Lond). 2020 Aug;40(8):374-379. doi: 10.1002/cac2.12077. Epub 2020 Jul 15.

DOI:10.1002/cac2.12077
PMID:32666636
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7405291/
Abstract
摘要

相似文献

1
Clinical outcomes of coronavirus disease 2019 (COVID-19) in cancer patients with prior exposure to immune checkpoint inhibitors.曾接触过免疫检查点抑制剂的癌症患者感染2019冠状病毒病（COVID-19）的临床结局
Cancer Commun (Lond). 2020 Aug;40(8):374-379. doi: 10.1002/cac2.12077. Epub 2020 Jul 15.
2
Coronavirus Disease 2019 (COVID-19) and Immune-Engaging Cancer Treatment.2019冠状病毒病（COVID-19）与免疫参与性癌症治疗
JAMA Oncol. 2020 Oct 1;6(10):1529-1530. doi: 10.1001/jamaoncol.2020.2367.
3
Potential protective and therapeutic role of immune checkpoint inhibitors against viral infections and COVID-19.免疫检查点抑制剂对病毒感染和新冠肺炎的潜在保护及治疗作用。
Immunotherapy. 2020 Oct;12(15):1111-1114. doi: 10.2217/imt-2020-0109. Epub 2020 Jun 29.
4
Checkpoint inhibitor pneumonitis mimicking COVID-19 infection during the COVID-19 pandemic.在新冠疫情期间，类似新冠病毒感染的检查点抑制剂肺炎。
Lung Cancer. 2020 Aug;146:376-377. doi: 10.1016/j.lungcan.2020.06.013. Epub 2020 Jun 17.
5
Developing a risk assessment score for patients with cancer during the coronavirus disease 2019 pandemic.制定 2019 冠状病毒病大流行期间癌症患者的风险评估评分。
Eur J Cancer. 2020 Aug;135:47-50. doi: 10.1016/j.ejca.2020.05.017. Epub 2020 May 31.
6
Disparities in Cancer Outcomes Due to COVID-19-A Tale of 2 Cities.COVID-19导致的癌症治疗结果差异——两个城市的故事
JAMA Oncol. 2020 Oct 1;6(10):1531-1532. doi: 10.1001/jamaoncol.2020.3327.
7
[Not Available].[无可用内容]。
Rev Med Suisse. 2020 May 27;16(695):1126.
8
SARS-CoV-2 positivity in a discharged COVID-19 patient: a case report.一名出院的新冠肺炎患者的严重急性呼吸综合征冠状病毒2阳性：病例报告
Clin Microbiol Infect. 2020 Aug;26(8):1115-1117. doi: 10.1016/j.cmi.2020.04.032. Epub 2020 Apr 29.
9
Rethinking Clinical Trials Reform During the COVID-19 Pandemic.新冠疫情期间对临床试验改革的反思
JAMA Oncol. 2020 Sep 1;6(9):1327-1329. doi: 10.1001/jamaoncol.2020.3142.
10
Oncology Care Delivery in the COVID-19 Pandemic: An Opportunity to Study Innovations and Outcomes.COVID-19大流行期间的肿瘤护理服务：研究创新与结果的契机。
JCO Oncol Pract. 2020 Aug;16(8):431-434. doi: 10.1200/OP.20.00326. Epub 2020 May 28.

引用本文的文献

1
Safety of immune checkpoint inhibitors in cancer patients with COVID-19: A review.免疫检查点抑制剂在新冠肺炎癌症患者中的安全性：综述
Medicine (Baltimore). 2025 Aug 8;104(32):e43579. doi: 10.1097/MD.0000000000043579.
2
Prognostic Factors for Survival or Severity After COVID-19 Infection in Cancer Patients: A Systematic Review and Meta-Analysis.癌症患者感染新型冠状病毒肺炎后的生存或严重程度的预后因素：一项系统评价和荟萃分析
J Rhinol. 2023 Jul;30(2):69-79. doi: 10.18787/jr.2023.00015. Epub 2023 Jul 28.
3
Cancer, more than a "COVID-19 co-morbidity".

本文引用的文献

1
Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study.中国湖北省癌症合并 COVID-19 患者的临床特征、结局和死亡危险因素：一项多中心、回顾性队列研究。
Lancet Oncol. 2020 Jul;21(7):904-913. doi: 10.1016/S1470-2045(20)30310-7. Epub 2020 May 29.
2
COVID-19 and cancer: do we really know what we think we know?COVID-19 与癌症：我们真的了解我们自以为了解的吗？
Nat Rev Clin Oncol. 2020 Jul;17(7):386-388. doi: 10.1038/s41571-020-0394-y.
3
Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers.
癌症，不仅仅是一种“新冠合并症”。
Front Oncol. 2023 Mar 13;13:1107384. doi: 10.3389/fonc.2023.1107384. eCollection 2023.
4
Colorectal cancer in patients with SARS-CoV-2: a systematic review and meta-analysis.感染新型冠状病毒2的患者中的结直肠癌：一项系统综述和荟萃分析。
Infect Agent Cancer. 2022 Sep 12;17(1):49. doi: 10.1186/s13027-022-00459-7.
5
COVID-19 Outcomes in Stage IV Cancer Patients Receiving Immune Checkpoint Inhibitors.接受免疫检查点抑制剂治疗的IV期癌症患者的COVID-19结局
SN Compr Clin Med. 2022;4(1):193. doi: 10.1007/s42399-022-01277-z. Epub 2022 Aug 26.
6
COVID-19 and Preexisting Comorbidities: Risks, Synergies, and Clinical Outcomes.COVID-19 与合并症：风险、协同作用和临床结局。
Front Immunol. 2022 May 27;13:890517. doi: 10.3389/fimmu.2022.890517. eCollection 2022.
7
Differences in Outcomes and Factors Associated With Mortality Among Patients With SARS-CoV-2 Infection and Cancer Compared With Those Without Cancer: A Systematic Review and Meta-analysis.比较 COVID-19 感染合并癌症与无癌症患者的结局差异及与死亡率相关的因素：系统评价和荟萃分析。
JAMA Netw Open. 2022 May 2;5(5):e2210880. doi: 10.1001/jamanetworkopen.2022.10880.
8
Impact of antitumor regimens on the outcomes of cancer patients with COVID-19: a pooled analysis.抗肿瘤方案对合并 COVID-19 癌症患者结局的影响：一项汇总分析。
J Zhejiang Univ Sci B. 2021 Oct 15;22(10):876-884. doi: 10.1631/jzus.B2100151.
9
Immune checkpoint inhibitors use and effects on prognosis of COVID-19 infection: a systematic review and meta-analysis.免疫检查点抑制剂在 COVID-19 感染中的应用及对预后的影响：一项系统评价和荟萃分析。
Immunotherapy. 2021 Oct;13(15):1271-1282. doi: 10.2217/imt-2021-0007. Epub 2021 Aug 25.
10
Mortality in Cancer Patients With COVID-19 Who Are Admitted to an ICU or Who Have Severe COVID-19: A Systematic Review and Meta-Analysis.癌症合并 COVID-19 患者的 ICU 住院或重症患者的死亡率：系统评价和荟萃分析。
JCO Glob Oncol. 2021 Aug;7:1286-1305. doi: 10.1200/GO.21.00072.
PD-1 阻断对肺癌患者 COVID-19 严重程度的影响。
Cancer Discov. 2020 Aug;10(8):1121-1128. doi: 10.1158/2159-8290.CD-20-0596. Epub 2020 May 12.
4
D-dimer is Associated with Severity of Coronavirus Disease 2019: A Pooled Analysis.D-二聚体与2019冠状病毒病的严重程度相关：一项汇总分析。
Thromb Haemost. 2020 May;120(5):876-878. doi: 10.1055/s-0040-1709650. Epub 2020 Apr 3.
5
SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China.SARS-CoV-2 在武汉一家三级医院癌症患者中的传播。
JAMA Oncol. 2020 Jul 1;6(7):1108-1110. doi: 10.1001/jamaoncol.2020.0980.
6
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.中国武汉成人 COVID-19 住院患者的临床病程和死亡危险因素：一项回顾性队列研究。
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
7
Histopathologic Changes and SARS-CoV-2 Immunostaining in the Lung of a Patient With COVID-19.新型冠状病毒肺炎患者肺部的组织病理学变化及严重急性呼吸综合征冠状病毒2免疫染色
Ann Intern Med. 2020 May 5;172(9):629-632. doi: 10.7326/M20-0533. Epub 2020 Mar 12.
8
Pathological findings of COVID-19 associated with acute respiratory distress syndrome.与急性呼吸窘迫综合征相关的新型冠状病毒肺炎的病理表现
Lancet Respir Med. 2020 Apr;8(4):420-422. doi: 10.1016/S2213-2600(20)30076-X. Epub 2020 Feb 18.
9
Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.《武汉 2019 年新型冠状病毒感染的肺炎 138 例住院患者临床特征分析》
JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585.
10
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.中国武汉地区 2019 年新型冠状病毒感染患者的临床特征。
Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.